168 related articles for article (PubMed ID: 38590144)
1. Pd
Carneiro TJ; Batista de Carvalho ALM; Vojtek M; Laginha RC; Marques MPM; Diniz C; Gil AM
J Med Chem; 2024 Apr; 67(8):6839-6853. PubMed ID: 38590144
[TBL] [Abstract][Full Text] [Related]
2. Impact of the Pd
Carneiro TJ; Araújo R; Vojtek M; Gonçalves-Monteiro S; de Carvalho ALMB; Marques MPM; Diniz C; Gil AM
Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639114
[TBL] [Abstract][Full Text] [Related]
3. Effect of Pd
Carneiro TJ; Vojtek M; Gonçalves-Monteiro S; Batista de Carvalho ALM; Marques MPM; Diniz C; Gil AM
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430252
[TBL] [Abstract][Full Text] [Related]
4. Impact of the Pd
Lamego I; Marques MP; Duarte IF; Martins AS; Oliveira H; Gil AM
J Proteome Res; 2017 Apr; 16(4):1773-1783. PubMed ID: 28244322
[TBL] [Abstract][Full Text] [Related]
5. Additive Pharmacological Interaction between Cisplatin (CDDP) and Histone Deacetylase Inhibitors (HDIs) in MDA-MB-231 Triple Negative Breast Cancer (TNBC) Cells with Altered Notch1 Activity-An Isobolographic Analysis.
Wawruszak A; Luszczki JJ; Kalafut J; Okla K; Halasa M; Rivero-Muller A; Stepulak A
Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31357442
[TBL] [Abstract][Full Text] [Related]
6. Biologic activity of a dinuclear Pd(II)-spermine complex toward human breast cancer.
Fiuza SM; Holy J; Batista de Carvalho LA; Marques MP
Chem Biol Drug Des; 2011 Jun; 77(6):477-88. PubMed ID: 21371266
[TBL] [Abstract][Full Text] [Related]
7. Impact of Conventional and Potential New Metal-Based Drugs on Lipid Metabolism in Osteosarcoma MG-63 Cells.
Bispo DSC; Correia M; Carneiro TJ; Martins AS; Reis AAN; Carvalho ALMB; Marques MPM; Gil AM
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139388
[TBL] [Abstract][Full Text] [Related]
8. Dual-target platinum(IV) complexes reverse cisplatin resistance in triple negative breast via inhibiting poly(ADP-ribose) polymerase (PARP-1) and enhancing DNA damage.
Li R; Zhao W; Jin C; Xiong H
Bioorg Chem; 2023 Apr; 133():106354. PubMed ID: 36720184
[TBL] [Abstract][Full Text] [Related]
9. Metabolic Impact of Anticancer Drugs Pd
Carneiro TJ; Vojtek M; Gonçalves-Monteiro S; Neves JR; Carvalho ALMB; Marques MPM; Diniz C; Gil AM
Pharmaceutics; 2022 Jan; 14(2):. PubMed ID: 35213994
[TBL] [Abstract][Full Text] [Related]
10. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapeutic response to cisplatin-like drugs in human breast cancer cells probed by vibrational microspectroscopy.
Batista de Carvalho AL; Pilling M; Gardner P; Doherty J; Cinque G; Wehbe K; Kelley C; Batista de Carvalho LA; Marques MP
Faraday Discuss; 2016 Jun; 187():273-98. PubMed ID: 27063935
[TBL] [Abstract][Full Text] [Related]
12. Anti-cancer effects of newly developed chemotherapeutic agent, glycoconjugated palladium (II) complex, against cisplatin-resistant gastric cancer cells.
Tanaka M; Kataoka H; Yano S; Ohi H; Kawamoto K; Shibahara T; Mizoshita T; Mori Y; Tanida S; Kamiya T; Joh T
BMC Cancer; 2013 May; 13():237. PubMed ID: 23672493
[TBL] [Abstract][Full Text] [Related]
13. Carbon ion beam combined with cisplatin effectively disrupts triple negative breast cancer stem-like cells in vitro.
Sai S; Vares G; Kim EH; Karasawa K; Wang B; Nenoi M; Horimoto Y; Hayashi M
Mol Cancer; 2015 Sep; 14():166. PubMed ID: 26338199
[TBL] [Abstract][Full Text] [Related]
14. Novel thiosemicarbazones induce high toxicity in estrogen-receptor-positive breast cancer cells (MCF7) and exacerbate cisplatin effectiveness in triple-negative breast (MDA-MB231) and lung adenocarcinoma (A549) cells.
Medina-Reyes EI; Mancera-Rodríguez MA; Delgado-Buenrostro NL; Moreno-Rodríguez A; Bautista-Martínez JL; Díaz-Velásquez CE; Martínez-Alarcón SA; Torrens H; de Los Ángeles Godínez-Rodríguez M; Terrazas-Valdés LI; Chirino YI; Vaca-Paniagua F
Invest New Drugs; 2020 Jun; 38(3):558-573. PubMed ID: 31177399
[TBL] [Abstract][Full Text] [Related]
15. The Cisplatin, 5-fluorouracil, Irinotecan, and Gemcitabine Treatment in Resistant 2D and 3D Model Triple Negative Breast Cancer Cell Line: ABCG2 Expression Data.
Ata FK; Yalcin S
Anticancer Agents Med Chem; 2022; 22(2):371-377. PubMed ID: 34315389
[TBL] [Abstract][Full Text] [Related]
16. Pd
Vojtek M; Gonçalves-Monteiro S; Šeminská P; Valová K; Bellón L; Dias-Pereira P; Marques F; Marques MPM; Batista de Carvalho ALM; Mota-Filipe H; Ferreira IMPLVO; Diniz C
Biomedicines; 2022 Jan; 10(2):. PubMed ID: 35203420
[TBL] [Abstract][Full Text] [Related]
17. Combined niclosamide with cisplatin inhibits epithelial-mesenchymal transition and tumor growth in cisplatin-resistant triple-negative breast cancer.
Liu J; Chen X; Ward T; Pegram M; Shen K
Tumour Biol; 2016 Jul; 37(7):9825-35. PubMed ID: 26810188
[TBL] [Abstract][Full Text] [Related]
18. Ailanthone inhibits cell growth and migration of cisplatin resistant bladder cancer cells through down-regulation of Nrf2, YAP, and c-Myc expression.
Daga M; Pizzimenti S; Dianzani C; Cucci MA; Cavalli R; Grattarola M; Ferrara B; Scariot V; Trotta F; Barrera G
Phytomedicine; 2019 Mar; 56():156-164. PubMed ID: 30668336
[TBL] [Abstract][Full Text] [Related]
19. Characterization of Pt-, Pd-spermine complexes for their effect on polyamine pathway and cisplatin resistance in A2780 ovarian carcinoma cells.
Tummala R; Diegelman P; Fiuza SM; Batista de Carvalho LA; Marques MP; Kramer DL; Clark K; Vujcic S; Porter CW; Pendyala L
Oncol Rep; 2010 Jul; 24(1):15-24. PubMed ID: 20514439
[TBL] [Abstract][Full Text] [Related]
20. Untargeted metabolomics analysis of omeprazole-enhanced chemosensitivity to cisplatin in mice with non-small cell lung cancer.
Gao H; Song Y; Ma J; Zhai J; Zhang Y; Qu X
Chem Biol Interact; 2022 Jun; 360():109933. PubMed ID: 35447140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
